A small fatality audit identified frequent additional drug exposure during long-acting buprenorphine treatment. Its death-only sample could not compare treatment mortality rates.
The selected records
Investigators began with postmortem buprenorphine or norbuprenorphine findings and examined opioid-agonist-treatment records. Ten people receiving long-acting injectable buprenorphine died during the study period, all in 2020.
Four deaths were classified as buprenorphine poisoning. Eight had findings of abused drugs, always including unprescribed benzodiazepines. Some additional buprenorphine use had not been known to the treating service.
A series of deaths is not a treatment cohort
The authors stated that the small number prevented statistical comparisons with other treatment medications or general mortality conclusions. A proportion among deceased patients cannot substitute for a rate among everyone receiving treatment.
The records also suggested gaps in psychosocial support and contact, but did not experimentally test a support intervention.
Forensic relevance
Preserve prescribed depot treatment, additional exposure, postmortem findings, and certified cause of death as distinct facts. The series supports examining co-use and continuity of support. It does not establish that injectable treatment is more dangerous than alternatives or that any detected benzodiazepine necessarily explains the death by itself.
Source paper
Original analysis of the supplied journal article, identified as PMC12532632.
Leave a Reply